A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas

Figure 4

Molecular and clinical correlation of the pseudogene methylation signature in TCGA samples. (a) Heatmaps of clinical and molecular features; each row represented a feature, and each column represented a sample, which was ordered by the assigned risk scores; (b) comparison of TMB between low-risk vs. high-risk tumors; and (c) representative gene set highly enriched in high-risk tumors; statistical data for GSEA are presented in Table S2.

(a)

(b)

(c)